Lonza and Crucell in cell culture medium marketing partnership

Published: 26-Sep-2008 Featured companies: Lonza

Lonza has agreed to manufacture, market and sell a cell culture medium developed by Crucell.


Lonza has agreed to manufacture, market and sell a cell culture medium developed by Crucell.

The PERMEXCISTM cell culture medium, developed by global biopharma company Crucell NV for PER.C6 cells, is a chemically defined cell culture medium that does not contain human- or animal-derived components.

The PERMEXCISTM medium has been designed for use in the large-scale manufacture of biopharmaceutical products, including vaccines. This novel medium has proven, in a comparison study performed by Crucell, to provide higher viral vaccine product yields in PER.C6-based manufacturing processes than some of the currently marketed

media for PER.C6 cells. "Lonza is pleased to enter into this agreement with Crucell N.V. Lonza is a leader in cell culture technology and media manufacturing, with a broad range of specialised media for all the major cell lines used in the biopharmaceutical industry. The new PER.C6 medium is a complementary addition to the Lonza Serum Free Medium product range," said Roel Gordijn, global sales and marketing director for media in the bioscience business of Lonza.

Featured companies

At Lonza, we enable a healthier world by supporting our healthcare customers on the path to commercialization. Our community of around 17,500 skilled employees work across a...
See more

You may also like

Finance

Johnson & Johnson to acquire Halda Therapeutics for $3.05bn, expanding US oncology drug pipeline

Read more
Johnson & Johnson has agreed to acquire Connecticut-based Halda Therapeutics for $3.05bn. The deal strengthens its oncology portfolio, including Halda’s first-in-class RIPTAC therapy for advanced prostate cancer

Trending Articles

  1. UK pharma shifts as Merck and AstraZeneca scale back: can CDMOs fill the gap? Recent major site withdrawals and investment pauses have raised concerns about the UK’s industrial strength. But CDMOs say agility, innovation and technical expertise could redefine how and where drugs are made
  2. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  3. Ardena strengthens leadership team with new quality and information officers Appointments reinforce focus on quality, compliance, and digital integration across global operations
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Embracing sustainable change through labelling choice Paavo Sillanpää, Senior Manager, Ecosystem Pharma and Healthcare, EMEIA, UPM Adhesive Materials, discusses the latest trends in pharmaceutical packaging and labelling and how producers can embrace future-focused solutions and sustainable options without compromising performance
  5. Christian Mias to succeed Andreas Reisse as CEO of SCHOTT Pharma Executive with over 20 years of management experience to lead pharmaceutical packaging and delivery systems company

Relevant companies

See more

You may also like

Finance

Johnson & Johnson to acquire Halda Therapeutics for $3.05bn, expanding US oncology drug pipeline

Johnson & Johnson has agreed to acquire Connecticut-based Halda Therapeutics for $3.05bn. The deal strengthens its oncology portfolio, including Halda’s first-in-class RIPTAC therapy for advanced prostate cancer
Pharma 5.0

Pistoia Alliance launches Phase 3 of CMC Process Ontology to bridge life sciences data gap and accelerate AI adoption

Backed by major pharma companies, the initiative aims to standardise experimental and process data across R&D and manufacturing, enabling automation and AI-ready data throughout the life sciences industry
Finance

Lonza to expand bioscience testing offering with the acquisition of Redberry

Acquisition to include Red One solid-phase cytometry platform for rapid sterility and bioburden testing, which expands Lonza’s portfolio of automated, scalable solutions for pharmaceutical quality control (QC)
Ingredients

De-risk early stage drug development with Lonza Advanced Synthesis

Located at stand 5.1B76, Lonza is set to shed light on the issues facing drug developers and how AI-assisted tools improve the process
Manufacturing

Lonza receives Swissmedic approval for new high-potency biologics filling line in Stein

Lonza’s state-of-the-art aseptic filling line in Stein, Switzerland, has been granted GMP approval by Swissmedic, expanding the CDMO’s capacity for biologics and antibody-drug conjugates while strengthening its integrated, end-to-end manufacturing offering
Manufacturing

RION engages Lonza to scale manufacturing exosome based therapeutics

Collaboration leverages RION’s proprietary biomanufacturing process to propel RION’s industry-leading clinical development pipeline towards late-phase trials and commercialisation for multiple regenerative medical conditions
Finance

Lonza delivers strong H1 2025 performance

Lonza delivers strong H1 2025 performance and upgrades 2025 full-year CDMO sales and margin outlook
Subscribe now